All News

April 22, 2010.

The Prescription Drug User Fee Act will expire in 2012 and FDA is working hard to renegotiate the act before that end date. The contenders: in one corner, the pharma industry; in the other, the general public and consumers - and just about everyone has an opinion about what needs to be changed.

Lilly's aggressive approach to shrinking the racial gap in drug trials might indicate big changes for the drugmaking process.

If your ?wonder drug? proves to have damaging side effects, do you have the measures in place to deal with the aftermath effectively? Chris Hart provides some pointers.

Sales reps faced another round of layoffs last week as Sanofi-Aventis restructures its sales force due to looming generic competition and a dip in sales.

HBA Woman of the Year

Success in this harsh climate depends on seeing business through the eye of the customer

IMS Health reports a nice increase in prescription sales from 2008 to 2009, even with a recession in full swing. That said, numbers are still well below the historic sales of a few years back, and it's anyone's guess if they will reach that high again.

Big thinker Bernard Munos delivers the goods.

Dutch pharma releases the same drug as a brand and a generic. Will this two-pronged attack work?

Proving that one good turn deserves another, Pfizer and GlaxoSmithKline announced that they would provide millions of doses of pneumonia vaccines to some of the world's most impoverished countries at massive discounts.

The number of consumers ditching their drugs at the pharmacy keeps climbing as the economy worsens.

A new report from IMS Health bumps the number of emerging markets to 17 and predicts that these nations will account for $90 billion in sales in the next four years. How will pharma take advantage of the opportunity?

NCM - Bold Brands Drive Revenue with Storytelling

2010 prix galien sponsor brochure with jay

Monday was a gloomy day for industry as two separate drug trials went belly up. AstraZeca's Recentin proved that it wasn't up-to-snuff compared with Avastin, and the Roche/Biogen Idec arthritis collaboration treatment, ocrelizumab, may have led to fatalities.

2010 prix galien sponsorship guide

Three ad agencies came up with two similarly designed ways of keeping track of online healthcare conversation, harnessing the power of social media sites like Twitter and Digg.

The Indian generic firm Ranbaxy was dealt another blow this week as its version of the enlarged prostate drug Flomax was denied approval in the US just as it was about to go to market.

Improve your leadership impact

Merck’s Man in Emerging Markets

Is it possible to remain commercially relevant just as a developer and distributor of drugs? Are there equivalent profits in a larger set of commitments?

Here are five pharmaceutical advertisement parodies that will make you howl 'till it hurts.

GSK is coming under serious fire again from the FDA and Senate, who say the company resorted to scientific flimflammery to keep researchers quiet about Avandia's safety risks.

The company released its numbers for 4Q '09, but is still hunting for more annual savings, which could come in the form of up to 15,000 job cuts.

Added funds for FDA to come from new user fees, largely for food and tobacco regulation.

The popular antidepressant is associated with up to 91 percent increase in risk of death in patients undergoing tamoxifen treatment for breast cancer.

February 10, 2010.

Gauging the Risk of Dual Enrollment - Independent Data Integrator - Clinical RSVP Whitepaper

Prix Galien 2010 Sponsorship Guide